Alosetron Market Size, Share and Trends Analysis Report, By Dosage type (0.5mg Tablet, and 1mg Tablet), By Applications (Chronic Irritable Bowel Syndrome, Visceral Pain, and Gastrointestinal Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),Forecast (2022-2028)

The global alosetron market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Alosetron the common name of alosetron and the product name isLotronex, it is a drug designed to treat women with Irritable Bowel Syndrome (IBS), and the effect of this is having diarrhea as a major problem. The increasing demand for oral contraceptives and the emergence of existing alosetron drugs driving the growth of the global alosetron market.

The major factor driving the demand for disease control and prevention vaccine, growing the technological advancements and new product launches in the vaccines to control, prevent, and gastrointestinal diseases across the globe are further driving the market growth. For instance, in May 2021, Ironwood Pharmaceuticals, Inc., has announced that with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. licensing to Teva abridged a new drug application (ANDA) requiring marketing permission for standard 72 mcg and theLINZESS is the prescribed brand in the US to treat elderly patients with (IBS- constipation).

Further, in January 2021, Sebela Pharmaceuticals announced the launch of SUTAB (sodium sulfate,magnesium sulfate tablets, and potassium chloride), modification of the first tablet alosetron and it obtain approval from the US FDA.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Dosage Type
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-Sebela Pharmaceuticals, Inc, Amneal Pharmaceuticals LLC, Par Pharmaceutical, Hikma Pharmaceuticals PLC.,and Pfizer Inc.,among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Alosetron Market Report by Segment

By Dosage Type

• 5mg Tablet
• 1mg Tablet

By Application

• Chronic Irritable Bowel Syndrome
• Visceral Pain
• Gastrointestinal Diseases

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Alosetron Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa